Displaying drugs 9076 - 9100 of 9162 in total
Interferon Gamma
Interferon gamma is a Type 1 inflammatory cytokine and the only type II interferon. It has antitumor properties, antiviral activities, and important immunoregulatory functions. The interferon is primarily produced by activated T lymphocytes and natural killer cells.
Investigational
R-348
Investigational
Axatilimab
Axatilimab is under investigation in clinical trial NCT04301778 (Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-embolization for Patients With Intrahepatic Cholangiocarcinoma).
Investigational
Sufugolix
Investigational
Spermine
Spermine is a spermidine-derived biogenic polyamine found as a polycation at all pH values. Found in various tissues and organisms, it often acts as an essential growth factor in some bacterial species. Spermine is associated with nucleic acids, particularly in viruses, and is thought to stabilize the helical structure.
Experimental
Nutraceutical
Cintredekin besudotox
Cintredekin besudotox has been developed as a specific tumor-targeting agent, which is administered by positive-pressure convection-enhanced delivery (CED) directly to brain tissue at risk for residual infiltrating glioblastoma multiforme (GBM) after tumor resection. Cintredekin besudotox is made from a human protein, Interleukin 13 (IL13), linked to a bacterial toxin, Pseudomonas...
Investigational
Avdoralimab
Avdoralimab is under investigation in clinical trial NCT04333914 (Prospective Study in Patients With Advanced or Metastatic Cancer and Sars-cov-2 Infection).
Investigational
TA-CIN
TA-CIN is a subunit vaccine comprising L2/E6/E7 proteins from Human Papillomavirus (HPV16), designed to generate a strong cellular immune response against HPV-infected cells.
Investigational
XR5944
XR5944 is a DNA bis-intercalating anticancer drug. It has both intercalating and antineoplastic activities.
Investigational
Tezacitabine
A synthetic purine nucleoside analogue with potential antineoplastic activity.
Investigational
Darapladib
Investigational
Taribavirin
Investigational
ACR-16
ACR-16 is under investigation by NeuroSearch. ACR16 has been successfully investigated in a Phase II multi-centre, randomised and placebo-controlled trial in patients with Huntington’s disease as well as in three Phase Ib studies within Huntington’s disease, Parkinson’s disease and schizophrenia respectively. ACR-16 is a dopamine stabilizer. ACR-16 is also being...
Investigational
Archexin
Investigational
Etazolate
EHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics.
Investigational
LGD-1550
LGD-1550 is an orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.
Investigational
Labetuzumab
Labetuzumab is a humanized monoclonal antibody to carcinoembryonic antigen that inhibits tumor growth. It is used in radioimmunotherapy.
Investigational
Caldaret
Investigational
Oregovomab
Oregovomab is a murine monoclonal antibody that attaches to the tumor-associated antigen CA125.
Investigational
CX516
Investigational
4-O-Demethylpenclomedine
Investigational
Tipapkinogene sovacivec
Investigational
MAS825
Investigational
DOTMP HO-166
DOTMP HO-166 is used in skeletal targeted radiotherapy (STR). SRT is designed to be used in combination with high-dose chemotherapy producing a direct therapeutic effect on the tumor sites in the bone plus a general bone-marrow effect to destroy myeloma cells in the bone marrow. It is an experimental therapy...
Investigational
Pegdinetanib
CT-322 is a proprietary Adnectin(TM) protein therapeutic that, in preclinical studies, specifically binds to vascular endothelial growth factor receptor 2 (VEGFR-2), which regulates the primary tumor angiogenesis pathway. As a result, CT-322 blocks all known ligands for VEGFR-2.
Investigational
Displaying drugs 9076 - 9100 of 9162 in total